WallStreetZenWallStreetZen

NASDAQ: XENE
Xenon Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for XENE

Based on 6 analysts offering 12 month price targets for Xenon Pharmaceuticals Inc.
Min Forecast
$47.00+42.17%
Avg Forecast
$51.67+56.28%
Max Forecast
$58.00+75.44%

Should I buy or sell XENE stock?

Based on 6 analysts offering ratings for Xenon Pharmaceuticals Inc.
Strong Buy
Strong Buy
3 analysts 50%
Buy
3 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their XENE stock forecasts and price targets.

XENE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
RBC Capital
Top 9%
92
BuyReiterates$51.00+54.26%2023-09-22
Cantor Fitzgerald
Top 6%
95
Strong BuyReiterates$58.00+75.44%2023-08-22
Wedbush
Bottom 4%
4
BuyReiterates$47.00+42.17%2023-08-10
Needham
Bottom 2%
2
BuyReiterates$50.00+51.24%2023-08-10
Guggenheim
Bottom 17%
17
Strong BuyReiterates$49.00+48.22%2023-06-15
JP Morgan
Bottom 6%
6
Strong BuyMaintains$55.00+66.36%2023-04-25

1 of 1

Forecast return on equity

Is XENE forecast to generate an efficient return?
Company
N/A
Industry
0.66%
Market
28.71%

Forecast return on assets

Is XENE forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.05%

XENE revenue growth forecast

How is XENE forecast to perform vs Biotechnology companies and vs the US market?
Company
748.34%
Industry
34.31%
Market
8.24%
XENE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
XENE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

XENE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
XENE$33.06$51.67+56.28%Strong Buy
GPCR$56.60$68.50+21.02%Strong Buy
GLPG$34.40$50.00+45.35%Hold
HRMY$32.44$55.88+72.24%Buy
IMCR$48.02$82.13+71.02%Strong Buy
View Top Biotech Stocks

Xenon Pharmaceuticals Stock Forecast FAQ

Is Xenon Pharmaceuticals Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: XENE) stock is to Strong Buy XENE stock.

Out of 6 analysts, 3 (50%) are recommending XENE as a Strong Buy, 3 (50%) are recommending XENE as a Buy, 0 (0%) are recommending XENE as a Hold, 0 (0%) are recommending XENE as a Sell, and 0 (0%) are recommending XENE as a Strong Sell.

If you're new to stock investing, here's how to buy Xenon Pharmaceuticals stock.

What is XENE's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: XENE) forecast ROE is N/A, which is considered weak.

What is XENE's Price Target?

According to 6 Wall Street analysts that have issued a 1 year XENE price target, the average XENE price target is $51.67, with the highest XENE stock price forecast at $58.00 and the lowest XENE stock price forecast at $47.00.

On average, Wall Street analysts predict that Xenon Pharmaceuticals's share price could reach $51.67 by Sep 22, 2024. The average Xenon Pharmaceuticals stock price prediction forecasts a potential upside of 56.28% from the current XENE share price of $33.06.

What is XENE's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: XENE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.05%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.